One study found systemic BEZ-235, a PI3K/mTOR inhibitor, by oral gavage to be effective in inhibiting the formation of papillomas and cSCCs in a chemically induced mouse model of cSCC, but to be ineffective in treating established lesions in preclinical models derived from human cSCC cell lines [250]. Here, PIK3CA is linked to skin squamous cell carcinoma.